BioWorld

Jan. 29, 2002

View Archived Issues

Achillion Closes $41M Round, Plans Phase III Trials This Year

Achillion Pharmaceuticals Inc. raised $41 million in a private round of financing that its CEO expects will allow it to take its lead anti-infective compound through Phase II trials and into Phase III before year’s end. Read More

Gryphon Sciences Gets $26M For Chemical Protein Products

Read More

FDA Says It Reduced Review Times As Called For In PDUFA

Read More

Genoptix Series B Raises $17M To Push Laser Cell Technology

Read More

Other News To Note

Read More